1. Arbor Realty Trust is facing increasing loan defaults and restructuring issues. 2. The company's balance sheet is shrinking due to deleveraging efforts, impacting its earnings and dividend capacity. 3. With the Fed likely to cut interest rates, ABR's net interest income is expected to decline, further straining its financial position.

1. Omeros has restructured its finances to extend debt maturities, alleviating immediate cash drain concerns. 2. Narsoplimab, its lead therapy, faces challenges in advancing past late-stage trials, with ongoing discussions with the FDA about resubmitting its BLA. 3. The company remains a high-risk investment with limited near-term catalysts and a reliance on FDA approval for its key asset.